tiprankstipranks

Analyst Profile

Followed by 592 followers
.
Matthew O'Brien

Matthew O'Brien

Piper Sandler
Wall Street Analyst
#2,065 out of 7,979 Wall Street Analysts
#4,089 out of 22,345 experts

Success Rate

48%
206 out of 433 transactions made a profit

Average Return

+2.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Matthew O'Brien's trades since 2012 and holding each position for 1 Year would result in 47.58% of your transactions generating a profit, with an average return of 2.6% per rating.

Stock Rating Distribution

1KRatings
84.33% Buy
15.48% Hold
0.19% Sell
Distribution of Matthew O'Brien's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Neuronetics
(STIM)
Rating:Buy
Date:Jul 14, 2020 - Jul 14, 2021
Return:+604.50%
The most profitable rating made by Matthew O'Brien

Matthew O'Brien's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
MAKO
Mako Surgical
May 08, 2012
Hold
Downgraded
2Ratings
0.00%
Xtant Medical Holdings
Aug 14, 2014
Buy
Reiterated
2Ratings
0.00%
BCR
CR Bard
Sep 16, 2014
Hold
Reiterated
1Ratings
0.00%
LDRH
LDR Holding
Jun 07, 2016
Hold
Downgraded
7Ratings
0.00%
CMSB
CMS Bancorp
Oct 31, 2016
Buy
Reiterated
1Ratings
0.00%
NVDQ
Novadaq
Jan 10, 2017
Buy
Reiterated
11Ratings
0.00%
ZLTQ
Zeltiq Aesthetics
Feb 13, 2017
Hold
Downgraded
15Ratings
0.00%
NXTM
NxStage Medical
May 09, 2017
Buy
Reiterated
10Ratings
0.00%
Resmed
Aug 02, 2017
Hold
Reiterated
$70.00
(-69.40% Downside)
8Ratings
0.00%
DENTSPLY SIRONA
Aug 09, 2017
Buy
Reiterated
$69.00
(130.54% Upside)
9Ratings
0.00%
List of latest recommendations made by Matthew O'Brien. Click to expand and see Matthew O'Brien's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >